LIGAND PHARMACEUTICALS INCORPORATED Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $90.06 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2026-02-27
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $90.06M.
- 2024-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $7.79M.
- 2023-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $2.95M.
- 2022-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $947.00K.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2025-12-31 | $90.06M 10-K · filed 2026-02-27 |
| 2024-12-31 | $7.79M 10-K · filed 2026-02-27 |
| 2023-12-31 | $2.95M 10-K · filed 2025-02-28 |
| 2022-12-31 | $947.00K 10-K · filed 2024-02-29 |
| 2021-12-31 | $18.67M 10-K · filed 2023-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-06 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-07 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-08 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-24 |